Please assess the completion status of the following clinical trial:

Trial Title: Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over or equal to the age of 18 years old who can understand the study protocol and are able to give consent~* Patients with an American Society of Anaesthesiology (ASA) classification 1 to 3~* Patients must have a preoperative oral 24 hour opioid consumption of less than or equal to 30 mg morphine equivalents~* Patients must be able to understand and be able to use patient controlled analgesia~* Patients must be undergoing a primary total knee arthroplasty with neuraxial anesthesia~Exclusion Criteria:~* Patients with a contraindication to neuraxial and/or regional anaesthesia~* Patients with an allergy to local anaesthetics~* Patients who have chronic pain not related to their knee joint~* Patients with chronic opioid use (daily or almost daily use \>3 months)~* Patients with contraindications to dexamethasone (allergy, infection, Insulin dependent Diabetes Mellitus)~* Patients with pre-existing neuropathy~* Patients with hepatic failure~* Patients with renal failure with eGFR\<60~* Patients with allergy to ketorolac or NSAIDs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Adductor Canal block (Type: ACTIVE_COMPARATOR): Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.
- Adductor canal block with dexamethasone (Type: ACTIVE_COMPARATOR): Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.
- Adductor canal catheter (Type: ACTIVE_COMPARATOR): Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).